Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects

Neuropsychopharmacology

Volumn 16, Issue 5, 1997, Pages 317-324

  Van Berckel, B N M ^a,b,c   Lipsch, C ^a,b   Timp, S ^a,b   Wied, C Gispen de ^a,b   Wynne, H ^a,b   Van Ree, J M ^a,b   Kahn, R S ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

cortisol; D cycloserine; LH; NMDA; schizophrenia

Indexed keywords

CYCLOSERINE; HYDROCORTISONE; LUTEINIZING HORMONE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PROLACTIN;

ADULT; ARTICLE; BEHAVIOR; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROENDOCRINOLOGY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030994293     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(96)00196-0     Document Type: Article

References (42)

1. Andreasen NC (1985): Comprehensive Assessment of Symptoms and History (CASH). Iowa City, University of Iowa
2. Arslan M, Pohl CR, Plant TM (1988): DL-2-amino-5-phosphonopentanoic acid, a specific N-methyl-D-aspartic acid receptor antagonist, suppresses pulsatile LH release in the rat. Neuroendocrinology 47:465-468
3. Arslan M, Pohl CR, Smith MS, Plant TM (1992): Studies of the role of the N-methyl-D-aspartate (NMDA) receptor in the hypothalamic control of prolactin secretion. Life Sci 50:295-300
4. Bond A, Lader M (1974): The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211-218
5. Carbone S, Szwarcfarb B, Rondina D, Feleder C, Moguilevsky JA (1996): Differential effects of the N-methyl-D-aspartate and non-N-methyl-D-Aspartate receptors of the excitatory amino acids system on LH and FSH secretion. Its effects on the hypothalamic luteinizing hormone releasing hormone during maturation in male rats. Brain Res 707:139-145
6. Chessell IP, Procter AW, Francis PT, Bowen DM (1991): D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res 565:345-348
7. Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL (1991): Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 30:1167-1171
8. Endicott J, Spitzer RL (1978): Diagnostic interview: The schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837-844
9. Flood JF, Morley JE, Lanthorn TH (1992): Effect on memory processing by D-cycloserine, and agonist of the NMDA/ glycine receptor. Eur J Pharmacol 221:249-254
10. Glazer WM, Charney DS, Heninger GR (1987): Noradrenergic function in schizophrenia. Arch Gen Psychiatry 44:898-904
11. Goff DC, Tsai GC, Manoach DS, Coyle JT (1995): dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213-1215
12. Hanngren H, Hansson E, Ullberg S (1961): Antibiotics Chemother 12:45-54
13. Henn FA (1995): The NMDA receptor as a site for psychopathology-primary or secondary role? Arch Gen Psychiatry 52:1008-1010
14. Hood WF, Compton RP, Ninahan JB (1989): D-cycloserine: A ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98:91-95
15. Ishimaru M, Kurumaji A, Toru M (1994): Increases in Strychnine-Insensitive Glycine Binding Sites in Cerebral Cortex of Chronic Schizophrenics - Evidence for Glutamate Hypothesis. Biol Psychiatry 35:84-95
16. Javitt DC, Zukin ST (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308
17. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer J (1994): Amelioration of Negative Symptoms in Schizophremia by Glycine. Am J Psychiatry 151:1234-1236
18. Jezova D, Oliver C, Jurcovicova J (1991): Stimulation of adrenocorticotropin but not prolactin and catecholamine release by N-methyl-aspartic acid. Neuroendocrinology 54:488-492
19. Jones RW, Wesnes KA, Kirby J (1991): Effects of NMDA modulation in scopolamine dementia. Ann N Y Acad Sci 640:241-244
20. Kahn RS, Wetzler S. (1991): m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 30:1139-1166.
21. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994): Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
22. Lahti AC, Koffel B, Laporte D, Tamminga CA (1995): Sub-anesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychoparmacology 13:9-19
23. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF (1962): Model psychoses and schizophrenia. Am J Psychiatry 119:61-67
24. Monahan JB, Handelmann GE, Hood WF, Cordi AA (1989): D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav 34:349-653.
25. Nishikawa T, Takashima M, Toru M (1983): Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 40:245-250
26. Olney JW, Farber NB (1995): Glutamate receptor by dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007
27. Overall JE, and Gorham DR. (1962): The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812
28. Petersen SL, McCrone S, Keller M, Gardner E. (1991): Rapid increase in LHRH mRNA levels following NMDA. Endocrinology 129:1679-1681
29. Pitkanen M, Sirvio J, Lahtinen H, Koivisto E, Riekkinen P. (1994): D-Cycloserine, a Partial Agonist at the Glycine Site, Enhances the Excitability of Dentate Granule Cells in Vivo in Rats. Eur J Pharmacol 253:125-129
30. Pittaluga A, Fedele E, Risiglione C, Raiteri M (1993): Age-related decrease of the NMDA receptor-mediated non-adrenaline release in rat hippocampus and partial restoration by D-cycloserine. Eur J Pharmacol 231:129-134
31. Rivas Salazar JL (1970): On cycloserine in the treatment of pulmonary tuberculosis and its use for postoperative protection. Scand J Respir Dis 71 (Suppl):314-324
32. Schainker BA, and Cicero TJ (1980): Acute central stimulation of luteinizing hormone by parenterally administered N-methyl-D,L-aspartic acid in the male rat. Brain Res 184:425-437
33. Sirvio J, Ekonsalo T, Riekkinen PJ, Lahtinen H, Riekkinen PS (1992): D-cycloserine, a modulator of the N-methyl-D-aspartate receptor, improves spatial learning in rats treated with muscarinic antagonist. Neurosci Lett 146:215-218
34. Thompson LT, Moskal JR, Disterhoft JF (1992): Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine. Nature 359:638-641.
35. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Mataga N, Ogawa A (1988): Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78:121-137
36. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT (1995): Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains. Arch Gen Psychiatry 52:829-836
37. Vallade LH (1959): La Neuro-toxicité de la Cycloserine Mise au point de ses manifestations cliniques et électroencéphalographiques d'après 30 publications françaises. La Presse Medicale 67(4):138-140
38. van Berckel BNM, Hijman R, van der Linden JA, Westenberg HGM, van Ree JM, Kahn RS (1996): Efficacy and Tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 40(12):1298-1300
39. van den Brink W, De Jong CAJ (1992): Nederlandse vertaling van de Structured Interview for DSM-III-R Personality: SIDP-R. IVB-Reeks 2
40. van den Pol AN, Wuarin JP, Dudek FE (1990): Glutamate, the dominant excitatory transmitter in neuroendocrine regulation. Science 250:1276-1278
41. Walker WC, Murdoch JM. (1957): Cycloserine in the Treatment of Pulmonary Tuberculosis. A Report on Toxicity. Tubercle (Lond) 38:297
42. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH (1990): D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res, 510:158-160